Results 201 to 210 of about 27,916,234 (409)
Glucocorticoid-Induced Inhibition of T Cell Growth Factor Production [PDF]
, 1979 Steven Gillis +2 more
openalex +1 more source
Molecular Oncology, EarlyView.Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker +14 more
wiley +1 more source
Molecular Oncology, EarlyView.In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen +13 more
wiley +1 more source
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera [PDF]
, 1979 Eiichi Nakayama +4 more
openalex +1 more source
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Molecular Oncology, EarlyView.Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha +6 more
wiley +1 more source
Ly and Ia antigen phenotypes of T cells involved in delayed-type hypersensitivity and in suppression. [PDF]
, 1976 Mathew A. Vadas +7 more
openalex +1 more source
A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini +11 more
wiley +1 more source
Early signaling defects in human T cells anergized by T cell presentation of autoantigen. [PDF]
, 1992 Major histocompatibility complex class II-positive human T cell clones are nontraditional antigen-presenting cells (APCs) that are able to simultaneously present and respond to peptide or degraded antigen, but are unable to process intact protein ...
Freeman, GJ +4 more
core
Qat-4 and Qat-5, new murine T-cell antigens governed by the Tla region and identified by monoclonal antibodies. [PDF]
, 1979 G J Hämmerling +2 more
openalex +1 more source